FDA Approves CARVYKTI® Breakthrough Therapy for Second-Line Multiple Myeloma
Legend Biotech Corporation has developed CARVYKTI®, a breakthrough therapy approved by the U.S. Food and Drug Administration (FDA) for treating relapsed or refractory multiple myeloma.
This innovative treatment targets B-cell Maturation Antigen (BCMA), a protein commonly found on multiple myeloma cells, using CAR-T cell technology.
It’s indicated for patients who have undergone at least one prior treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Its approval was based on the promising results of the CARTITUDE-4 study, which showed significant improvements in progression-free survival compared to standard treatment regimens.
The therapy involves collecting a patient's own T-cells, genetically modifying them to express a chimeric antigen receptor (CAR) specific to BCMA, and reinfusing them into the patient.
This engineered CAR-T cell therapy seeks out and destroys BCMA-expressing multiple myeloma cells.
Despite its efficacy, CARVYKTI® comes with a comprehensive safety profile, including warnings for potential severe side effects such as cytokine release syndrome and neurotoxicity.
Common adverse reactions observed include fever, cytokine release syndrome, and hypogammaglobulinemia.
Infections, prolonged cytopenias, hypersensitivity reactions, and secondary malignancies. These risks necessitate careful patient selection, monitoring, and management in specialized healthcare settings under a Risk Evaluation and Mitigation Strategy (REMS).
Legend Biotech has scaled up its manufacturing capabilities to meet the anticipated demand for CARVYKTI®, ensuring broader access to this advanced therapy for eligible patients with multiple myeloma.
